Gena Wang
Stock Analyst at Barclays
(3.21)
# 1,171
Out of 5,006 analysts
222
Total ratings
44.83%
Success rate
2.39%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Gena Wang
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| CYTK Cytokinetics | Maintains: Overweight | $71 → $82 | $59.94 | +36.80% | 4 | Oct 6, 2025 | |
| KOD Kodiak Sciences | Upgrades: Equal-Weight | $7 → $17 | $13.96 | +21.78% | 10 | Sep 25, 2025 | |
| IONS Ionis Pharmaceuticals | Maintains: Overweight | $78 → $80 | $69.21 | +15.59% | 13 | Sep 23, 2025 | |
| RGNX REGENXBIO | Maintains: Overweight | $50 → $37 | $10.50 | +252.38% | 7 | Aug 8, 2025 | |
| RNA Avidity Biosciences | Maintains: Overweight | $59 → $62 | $46.36 | +33.74% | 4 | Aug 8, 2025 | |
| CRSP CRISPR Therapeutics AG | Maintains: Equal-Weight | $42 → $56 | $69.30 | -19.19% | 17 | Aug 6, 2025 | |
| BEAM Beam Therapeutics | Maintains: Equal-Weight | $25 → $21 | $25.05 | -16.17% | 10 | Aug 6, 2025 | |
| MRNA Moderna | Maintains: Equal-Weight | $40 → $31 | $27.19 | +14.01% | 10 | Aug 4, 2025 | |
| ALNY Alnylam Pharmaceuticals | Maintains: Overweight | $329 → $460 | $456.72 | +0.72% | 8 | Aug 1, 2025 | |
| SRPT Sarepta Therapeutics | Upgrades: Equal-Weight | $10 → $22 | $22.87 | -3.80% | 15 | Jul 30, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $42 → $46 | $63.21 | -27.22% | 16 | Jul 29, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $15 → $10 | $5.28 | +89.39% | 7 | May 16, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $9 → $5 | $0.65 | +663.48% | 4 | May 14, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $5 → $4 | $3.75 | +6.67% | 4 | May 13, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $45 → $38 | $8.36 | +354.55% | 2 | May 9, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $8 → $11 | $7.01 | +57.03% | 10 | May 7, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $26 → $31 | $5.59 | +454.56% | 6 | Feb 28, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $55 → $26 | $20.31 | +28.02% | 7 | Feb 28, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $435 → $467 | $410.58 | +13.74% | 17 | Feb 11, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $5 → $3 | $3.83 | -21.57% | 9 | Dec 13, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $110 → $86 | $55.22 | +55.74% | 15 | Oct 4, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $83 → $81 | $29.82 | +171.68% | 6 | Aug 5, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $93 → $94 | $31.51 | +198.32% | 6 | Jan 24, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $7 → $9 | $16.37 | -45.02% | 1 | Dec 22, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Equal-Weight | $16 → $25 | $20.82 | +20.08% | 5 | Nov 2, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $32 → $18 | $8.40 | +114.29% | 2 | May 13, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Underweight | $21 → $9 | $5.08 | +77.34% | 6 | Aug 9, 2019 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $275 | $5.26 | +5,133.11% | 1 | Jan 6, 2017 |
Cytokinetics
Oct 6, 2025
Maintains: Overweight
Price Target: $71 → $82
Current: $59.94
Upside: +36.80%
Kodiak Sciences
Sep 25, 2025
Upgrades: Equal-Weight
Price Target: $7 → $17
Current: $13.96
Upside: +21.78%
Ionis Pharmaceuticals
Sep 23, 2025
Maintains: Overweight
Price Target: $78 → $80
Current: $69.21
Upside: +15.59%
REGENXBIO
Aug 8, 2025
Maintains: Overweight
Price Target: $50 → $37
Current: $10.50
Upside: +252.38%
Avidity Biosciences
Aug 8, 2025
Maintains: Overweight
Price Target: $59 → $62
Current: $46.36
Upside: +33.74%
CRISPR Therapeutics AG
Aug 6, 2025
Maintains: Equal-Weight
Price Target: $42 → $56
Current: $69.30
Upside: -19.19%
Beam Therapeutics
Aug 6, 2025
Maintains: Equal-Weight
Price Target: $25 → $21
Current: $25.05
Upside: -16.17%
Moderna
Aug 4, 2025
Maintains: Equal-Weight
Price Target: $40 → $31
Current: $27.19
Upside: +14.01%
Alnylam Pharmaceuticals
Aug 1, 2025
Maintains: Overweight
Price Target: $329 → $460
Current: $456.72
Upside: +0.72%
Sarepta Therapeutics
Jul 30, 2025
Upgrades: Equal-Weight
Price Target: $10 → $22
Current: $22.87
Upside: -3.80%
Jul 29, 2025
Maintains: Equal-Weight
Price Target: $42 → $46
Current: $63.21
Upside: -27.22%
May 16, 2025
Maintains: Overweight
Price Target: $15 → $10
Current: $5.28
Upside: +89.39%
May 14, 2025
Maintains: Overweight
Price Target: $9 → $5
Current: $0.65
Upside: +663.48%
May 13, 2025
Maintains: Overweight
Price Target: $5 → $4
Current: $3.75
Upside: +6.67%
May 9, 2025
Maintains: Overweight
Price Target: $45 → $38
Current: $8.36
Upside: +354.55%
May 7, 2025
Maintains: Equal-Weight
Price Target: $8 → $11
Current: $7.01
Upside: +57.03%
Feb 28, 2025
Maintains: Overweight
Price Target: $26 → $31
Current: $5.59
Upside: +454.56%
Feb 28, 2025
Maintains: Overweight
Price Target: $55 → $26
Current: $20.31
Upside: +28.02%
Feb 11, 2025
Maintains: Equal-Weight
Price Target: $435 → $467
Current: $410.58
Upside: +13.74%
Dec 13, 2024
Maintains: Equal-Weight
Price Target: $5 → $3
Current: $3.83
Upside: -21.57%
Oct 4, 2024
Maintains: Overweight
Price Target: $110 → $86
Current: $55.22
Upside: +55.74%
Aug 5, 2024
Maintains: Overweight
Price Target: $83 → $81
Current: $29.82
Upside: +171.68%
Jan 24, 2024
Maintains: Overweight
Price Target: $93 → $94
Current: $31.51
Upside: +198.32%
Dec 22, 2022
Maintains: Equal-Weight
Price Target: $7 → $9
Current: $16.37
Upside: -45.02%
Nov 2, 2022
Upgrades: Equal-Weight
Price Target: $16 → $25
Current: $20.82
Upside: +20.08%
May 13, 2022
Maintains: Overweight
Price Target: $32 → $18
Current: $8.40
Upside: +114.29%
Aug 9, 2019
Maintains: Underweight
Price Target: $21 → $9
Current: $5.08
Upside: +77.34%
Jan 6, 2017
Initiates: Buy
Price Target: $275
Current: $5.26
Upside: +5,133.11%